GSK (GlaxoSmithKline) J.P. Morgan UK Leaders Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
GSK session here at the 2026 U.K. Leaders Conference. I'm Zain Ebrahim from the European Pharma team here at J.P. Morgan, and it's my great pleasure to welcome the CFO of GSK, Julie Brown. Julie, maybe over to you for some opening remarks.
Hi. Hi, Zain. Hi, everybody. Nice to see you all on this latest slot. Just by way of opening, I'll only say a few things because I know you've got lots of questions. I think in a nutshell, we've been incredibly busy this year. We set about really, really re-energizing R&D, and we had two major work streams running in the company from the beginning. One was all about strategic portfolio management in R&D and what could we accelerate. The other work stream was all about simplifying the organization and how could we fund the growth in R&D by simplifying what we were doing day-to-day.
Those two work streams came together when we announced in July the Accelerate Growth programme, which was all about investing more in R&D, but at the same time, saving GBP 1.9 billion through the Accelerate Growth programme, the majority of which would be then invested in the assets that we'd identified for acceleration. Now we have basically, by the end of this year, 22 phase III starts, that are going to be completed by the end of this year. We're delighted with that because last year we had about seven, and the previous year we had about six. It's a multiple times acceleration.
At the same time as investing significantly in R&D, we have been able to improve the sales over the last five years by more than 8%, the profit by more than 13%, and the margin by more than 500 basis points at the same time as R&D's gone from a teen percentage of sales to basically just over 20% of sales. That's what we've been doing together with a number of acquisitions, as I mentioned, and happy to hand over to Zain for questions.
Perfect. That's a great introduction. This time last year we were here, and consensus for 2031 was around GBP 34.8 billion. It's now at about GBP 36.6 billion. My numbers have gone up a couple of billion as well. What do you think the market is still underappreciating as it relates to your greater than GBP 40 billion sales target for 2031? Where do you see the most upside to consensus?
Yes, absolutely. The first thing to say is that when we give guidance out to 2031, we always do it on a probability of technical and regulatory success basis. This isn't a gross number. This is a net number taking the risks and the stage of development into consideration. It's usual that consensus is lower than the company. It can be quite usual because obviously the market waits for the readouts. But the biggest difference, there are small differences across the board, but the biggest difference, if I was to isolate it would be in oncology. This is largely because GSK is a smaller player in oncology. We've been building the oncology franchise.
We've now got a series of assets that could be very meaningful to the company, and there's one in particular I would highlight, which is B7-H3, which is expressed in a series of solid tumor types. We've got some incredible data readouts associated with that already from ourselves and our partner, Hansoh. In other words, we believe over the course of the next number of years, it may take two or three years, this will start to make a difference to consensus numbers together with the fact that we've got six products in the launch phase or very close to regulatory approval, which will already start to show the commercial potential of those assets. At that point, we would expect there to be moves in consensus. So consensus has moved, I think, from about GBP 33 billion to now, as you say, GBP 36.6 billion.
I make a joke to my team that I don't measure it every day, but we know the numbers to the next decimal place. I also, obviously, consensus margins out to 2030 have moved from 25% to 30%. So there has been quite a bit of movement over the last few years.
And you touched on the Accelerate Growth programme that you outlined with the Q2 results and the savings that it will bring to GSK in terms of GBP 1.9 billion annual savings when you get there.
Yeah. Can you talk through maybe how much that's going to cost you, just to remind us there, and where the savings are going to come from?
Is it across both the supply chain, SG&A? How we should think about that, and how we should think about the R&D as a percentage of sales over the medium term?
Okay. Yeah. So we've started the program in July, and it's progressing probably slightly ahead of schedule. It's going really well. We said GBP 1.9 billion would be achieved by 2029, 90% of which will be delivered by 2028. We're actually potentially ahead of that schedule, so already, the whole organization is geared towards delivering this in a very productive way. In terms of the major content, in terms of where it's coming from, we've put a lot of emphasis on streamlining support services. So any area of the business that is supporting what you might call the frontline, R&D, commercial activity, is looking for ways in which you can streamline. If I take some of our functions like finance, HR, legal, compliance, et cetera, they're already top quartile, but they will be even better than that as a result of this program.
The second thing we're doing is we are streamlining supply chain. Obviously, we are moving increasingly to long-acting and long-acting injectables, which means there are fewer doses going through our factories, which means we've got an opportunity to make streamlining in that area. And then we're increasingly using technology. I mean, Zain and I were talking about technology just earlier in the break. Increasingly using technology and AI to change the way we work, which gives us, again, the ability to deliver some significant savings. What we decided to do was say that the majority of the money would go towards the acceleration of R&D, because we believe that gives shareholders the best value.
However, we also appreciated that we do face a patent expiry of dolutegravir from 2028 to 2030. As a consequence of that, we decided that the margin will not just be stable through that period, but there is an opportunity for some of these savings to drop through during that period, which means the margin will be stable to improving. We will have a choice as we get closer to that as to how much we drop through and how much we retain for investment. That is the reason behind it. But yeah, very comprehensive program involving all parts of the organization. I think the reason it is energized everybody, it is not just a savings program, it is a savings program that is causing the acceleration in R&D that brings the products to patients far more quickly.
I definitely want to go through some of those products, but maybe to pick up on one of the elements you touched on in terms of using technology to change the way that you are working within GSK. Given how topical it is, can you maybe expand on that in terms of how is it changing the way you are thinking about SG&A? Where are you seeing the most potential for savings in those cost lines?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
